CRB Inverbío
Cross Road Biotech Inversiones Biotecnológicas, known as CRB Inverbío, is a venture capital firm based in Madrid, Spain, founded in 2001. The firm specializes in investing in seed, startup, and early-stage companies primarily within the healthcare and life sciences sectors, including pharmaceuticals, biotechnology, med tech, digital health, and diagnostics. CRB Inverbío focuses on innovative projects that address unmet medical needs and typically invests between €0.5 million and €3 million. The firm seeks to support companies developing medical products, therapeutic solutions, and diagnostic technologies, as well as applications of biotechnology in agriculture and animal health. With a commitment to backing projects led by experienced scientists and entrepreneurs, CRB Inverbío provides not only financial resources but also management support and strategic advice, aiming for exits within three to five years.
Aglaris is developing an automated cell culture bioreactor for the mass production of human stem cells. Aglaris produces equipment to ensure cell and tissue culture is an easy, problem-free task. By automating and controlling the cell culture processes, we can obtain cells and tissues with sufficient quality to revitalize regenerative medicine and cell therapies. The technology used by our equipment is unique and is protected by international patents.
Mecwins S.L. is a Spanish company based in Tres Cantos that specializes in nanotechnological solutions aimed at researchers across various scientific fields. Founded in 2008, the company has developed the SCALA platform, an ultrasensitive technology that characterizes mechanical-based sensor devices such as cantilevers and membranes in diverse environments including air, liquid, and vacuum. The SCALA platform features modules for dynamics, liquid measurement, and 3D imaging, enabling applications in biochip development, MEMS monitoring, biomedicine, drug discovery, and environmental analysis. Mecwins also produces ultra-high sensitive immunoassays targeting oncology, cardiovascular, and infectious diseases, serving researchers in materials science, biochemistry, medical diagnostics, and food science through its representatives in Spain.
Nuubo is a Spanish medical device company that designs, manufactures, and sells wearable wireless technologies aimed at monitoring cardiac health for prevention, diagnosis, and rehabilitation. The company's flagship product, the nECG DYNAMIC PLATFORM, consists of three components: a biomedical garment that captures electrocardiogram (ECG) signals without disrupting daily activities, a wireless device that continuously records and transmits this data, and analysis software that utilizes artificial intelligence for interpretation. Nuubo's solutions enable real-time ECG monitoring, allowing for longer monitoring periods while ensuring patient comfort. The company primarily serves professional sports teams and hospitals and has been operational since its founding in 2005, with its headquarters located in Madrid, Spain.
Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.
TCD Pharma, established in 2005, is a biotechnology company based in Spain that focuses on developing innovative therapies for oncology, particularly targeting unmet medical needs. The company's lead product, TCD-717, is currently in clinical trials. TCD Pharma aims to position itself as a key partner in oncology drug discovery and development by building its pipeline through in-licensing and strategic partnerships. The firm collaborates with premier Contract Research Organizations to leverage resources, significantly reducing the risks and costs associated with drug development. TCD Pharma's drug development center plays a critical role in advancing cancer treatments by providing enzymes that regulate phosphatidylcholine production, essential for cell membrane formation and proliferation. Through its strategic initiatives, TCD Pharma is dedicated to enhancing patient access to effective oncology therapies.
TCD Pharma, established in 2005, is a biotechnology company based in Spain that focuses on developing innovative therapies for oncology, particularly targeting unmet medical needs. The company's lead product, TCD-717, is currently in clinical trials. TCD Pharma aims to position itself as a key partner in oncology drug discovery and development by building its pipeline through in-licensing and strategic partnerships. The firm collaborates with premier Contract Research Organizations to leverage resources, significantly reducing the risks and costs associated with drug development. TCD Pharma's drug development center plays a critical role in advancing cancer treatments by providing enzymes that regulate phosphatidylcholine production, essential for cell membrane formation and proliferation. Through its strategic initiatives, TCD Pharma is dedicated to enhancing patient access to effective oncology therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.